Stock Analysis
- Hong Kong
- /
- Healthcare Services
- /
- SEHK:9885
YSB First Half 2024 Earnings: EPS: CN¥0.034 (vs CN¥23.70 loss in 1H 2023)
YSB (HKG:9885) First Half 2024 Results
Key Financial Results
- Revenue: CN¥8.81b (up 11% from 1H 2023).
- Net income: CN¥21.8m (up from CN¥3.17b loss in 1H 2023).
- Profit margin: 0.2% (up from net loss in 1H 2023).
- EPS: CN¥0.034 (up from CN¥23.70 loss in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
YSB's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with YSB.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:9885
YSB
Develops digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China.